Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 8/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | LYN | P07948 | 1/20 | 0.42 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.33 |
| ▸ | JAK1 | P23458 | 2/20 | 0.32 |
| ▸ | JAK3 | P52333 | 2/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15220155 | 0.91 | SYK (0.46) | SYKEGFRJAK2LCKLYN | |
| SCHEMBL15220218 | 0.90 | SYK (0.46) | SYKEGFRJAK2LCKLYN | |
| SCHEMBL15220111 | 0.82 | SYK (0.48) | SYKEGFRJAK2LCKLYN | |
| SCHEMBL15212247 | 0.81 | SYK (0.44) | SYKEGFRJAK2LCKLYN | |
| SCHEMBL15212360 | 0.78 | SYK (0.49) | SYKEGFRJAK2LCKLYN | |
| SCHEMBL15212485 | 0.74 | SYK (0.53) | SYKEGFRJAK2LCKLYN | |
| SCHEMBL15212505 | 0.74 | SYK (0.46) | SYKEGFRJAK2LCKLYN | |
| SCHEMBL2103987 | 0.72 | TRPV1 (0.51) | SYKEGFRJAK2LCKLYN | |
| SCHEMBL655687 | 0.71 | SYK (0.64) | SYKEGFRJAK2LCKLYN | |
| SCHEMBL15212398 | 0.71 | SYK (0.51) | SYKEGFRJAK2LCKLYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2817306-B1 | CYCLIC DIAMINOPYRIMIDINE DERIVATIVES AS SYK INHIBITORS | MERCK PATENT GMBH (DE) | 2015-09-16 | — | — | EP | disclosed |
| US-9073944-B2 | Cyclic diaminopyrimidine derivatives | MERCK PATENT GMBH (DE) | 2015-07-07 | — | — | US | disclosed |
| US-9073944-B2 | Cyclic diaminopyrimidine derivatives | MERCK PATENT GMBH (DE) | 2015-07-07 | — | — | US | disclosed |
| US-20150025066-A1 | CYCLIC DIAMINOPYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-01-22 | — | — | US | disclosed |
| US-20150025066-A1 | CYCLIC DIAMINOPYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-01-22 | — | — | US | disclosed |
| WO-2013126132-A1 | CYCLIC DIAMINOPYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025066-A1 | CYCLIC DIAMINOPYRIMIDINE DERIVATIVES | SYK, BTK, LYN | SYK 1/4885EGFR 929/4885JAK2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.